BERKELEY, Calif., Jan. 11, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced several presentations that highlight advances in the company's biodefense program and particularly in the development of XOMA 3AB, a three antibody formulation that binds to distinct regions of botulinum toxin type A. Among these will be an invited oral presentation describing the successful lyophilization of XOMA 3AB and studies demonstrating the stability of this formulation over time stored at a wide range of temperatures. The presentations will be made at the Fifth Annual Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Stakeholders Workshop and BARDA Industry Day, January 10 to 12, 2011 in Washington, DC.
